¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"insoluble fibrin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® fibrin ÇÑ±Û ¼¶À¯¼Ò
¼³¸í   
  Çǰ¡ ±»À» ¶§ ¼¶À¯¼Ò¿¡ Æ®·ÒºóÀÌ ÀÛ¿ëÇÏ¿© »ý±â´Â ¼¶À¯ °°Àº ´Ü¹éÁú. ¹«»öÀ̳ª ¿¯Àº È²»öÀ» ¶í °íü·Î, ¹°¿¡ Àß ³ìÁö ¾ÊÀ¸¸ç Ç÷±¸¿Í ¾ûŰ¾î ÇǸ¦ ±»°Ô ÇÏ¿© ÃâÇ÷À» ±×Ä¡°Ô ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cold-insoluble immunoglobulin
    ÇÑ·©ºÒ¿ë¸é¿ª±Û·ÎºÒ¸°
  • fibrin
    ¼¶À¯¼Ò, ÇǺ기
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü, ÇǺ기Ç÷Àü
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cold-insoluble immunoglobulin
    ÇÑ·©ºÒ¿ë¸é¿ª±Û·ÎºÒ¸°
  • fibrin
    ¼¶À¯¼Ò
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insoluble
    ºÒ¿ë¼º(ÝÕé»àõ)(ÀÇ).
  • insoluble protein
    ºÒ¿ë¼º ´Ü¹é(Áú).
  • Fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • Fibrin-stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­)
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cold-insoluble immunoglobulin
    ÇÑ·©ºÒÀÀ¼º ¸é¿ª±Û·ÎºÒ¸°
  • insoluble
    ºÒ¿ë¼º(ÝÕé»àõ)(ÀÇ).
  • insoluble protein
    ºÒ¿ë¼º ´Ü¹é(Áú).
  • carmine fibrin
    Ä«¸£¹Î¼¶À¯¼Ò(¡­àéë«áÈ).
  • crystal fibrin
    °áÁ¤¼¶À¯¼Ò, ¼öÁ¤Ã¼¼¶À¯¼Ò(¡­àéë«áÈ).
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ), È­À̺기.
  • fibrin abnormality
    ¼¶À¯¼ÒÀÌ»ó
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«, ¼¶À¯¼ÒÀÀ°í
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«(¡­ëêÎÔ).
  • fibrin degradation product
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin stabilizing factor =FSF
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­), ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤ÀÎÀÚ, ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insoluble fibrin
    ºÒ¿ë¼º(ÝÕéÁàõ) È­À̺기
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cold-insoluble globulin
    ³ÃºÒ¿ë¼º(Ò²ÝÕéÁàõ) ±Û·ÎºÒ¸°
  • insoluble enzyme
    ºÒ¿ë¼ºÈ¿¼Ò(ÝÕéÁàõý£áÈ)
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • fibrin monomer
    ¼¶À¯¼Ò ´Ü·®Ã¼(àéë«áÈÓ¤Õáô÷)
  • fibrin polymer
    ¼¶À¯¼Ò ÁßÇÕü(àéë«áÈñìùêô÷)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • soluble fibrin
    "°¡¿ë(ʦéÁ)ÇǺ기, °¡¿ë ¼¶À¯¼Ò(ʦéÁàéë«áÈ)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • insoluble
    ºÒ¿ë¼ºÀÇ
  • fibrin
    ¼¶À¯¼Ò, È­À̺기
  • fibrin plug
    È­À̺기ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin sealant
    ¼¶À¯¼Ò¹ÐÆóÁ¦(¹ÐºÀÁ¦)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SFC soluble fibrin complex; soluble fibrin-fibrinogen complex; spinal fluid count
BII beat inclusion index; Billroth II [operation]; butanol-insoluble iodine
CIG cold-insoluble globulin
IBG insoluble bone gelatin
insol insoluble
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CIG Cold insoluble globulin
WI water insoluble
FDP Fibrin Degradation Product
FbDP Fibrin Degradation Products
FS Fibrin Sealant
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • insoluble
    ºÒ¿ë¼ºÀÇ
  • insoluble polymer
    ºÒ¿ë¼º ÁßÇÕÁ¦
  • crystal fibrin
    °áÁ¤ ¼¶À¯¼Ò, ¼öÁ¤Ã¼ ¼¶À¯¼Ò
  • fibrin bodies of pleura
    È丷 ¼¶À¯ ¼Òü
    È丷°­ ±âÀúºÎ±Ù¿¡ ÀÖ´Â °¡µ¿¼º ¶Ç´Â Á¡Âø¼º, ±¸»ó, µ¿Áú¼º, ±×¸®°í ÇѰ谡 ¸íÈ®ÇÑ À¯¹éü·Î¼­, È丷 »ïÃâ¾×, ±âÈä ¶Ç´Â Ç÷±âÈäÁõ¿¡¼­ ÀÌÂ÷ÀûÀ¸·Î ¹ß»ýÇÑ´Ù.
  • fibrin plug
    È­À̺기 ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin thrombus
    È­À̺êÁø Ç÷Àü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
cold insoluble globulin <haematology> Name, now obsolete, originally given to fibronectin prepared from cryoprecipitate.
(18 Nov 1997)
insoluble Not soluble.
(05 Mar 2000)
insoluble soap Soap made with a fatty acid and an earthy or metallic base (iron or calcium salts of fatty acids).
(05 Mar 2000)
human fibrin foam A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant.
(05 Mar 2000)
fibrin <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot.
(12 Nov 1997)
fibrin calculus A urinary calculus formed largely from fibrinogen in blood.
(05 Mar 2000)
fibrin degradation products <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot.
Normal value is less than 10 mcg/ml (micrograms per millilitre).
They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia.
Acronym: FDP
(23 Sep 2002)
fibrin destabilase <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin
Pharmacological action: fibrinolytic agents
Registry number: EC 3.4.99.-
Synonym: destabilase
(26 Jun 1999)
fibrin fibrinogen degradation products <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis.
Pharmacological action: antithrombins.
(12 Dec 1998)
fibrin foam <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
fibrinogen-fibrin conversion syndrome <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma.
(05 Mar 2000)
fibrin-stabilizing factor <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
Chemical name: Blood-coagulation factor XIII
(12 Dec 1998)
fibrin thrombus A thrombus formed by repeated deposits of fibrin from the circulating blood; it usually does not completely occlude the vessel.
(05 Mar 2000)
fibrin tissue adhesive <chemical> An autologous or commercial tissue adhesive containing fibrinogen and thrombin. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, factor viii, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agent such as aprotinin. Mixing of the two components promotes clotting and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, haemostasis, and wound healing.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • insoluble
    ¿ëÇØÇÏÁö ¾Ê´Â
  • insoluble
    ³ìÁö ¾Ê´Â;ºÒ¿ëÇØ¼ºÀÇ;Ç®¼ö¾ø´Â;ÇØ°á(¼³¸í,ÇØ¼®)ÇÒ ¼ö ¾ø´Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á